Chen-Jie Qiu1,2, Xue-Bing Wang1,2, Zi-Ruo Zheng1,2, Chao-Zhi Yang1,2, Kai Lin1,2, Kai Zhang1,2, Min Tu1,2, Kui-Rong Jiang3,4, Wen-Tao Gao5,6. 1. Pancreas Center, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, Jiangsu, China. 2. Pancreas Institute, Nanjing Medical University, Nanjing, Jiangsu, China. 3. Pancreas Center, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, Jiangsu, China. jiangkuirong@njmu.edu.cn. 4. Pancreas Institute, Nanjing Medical University, Nanjing, Jiangsu, China. jiangkuirong@njmu.edu.cn. 5. Pancreas Center, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, Jiangsu, China. gao11@hotmail.com. 6. Pancreas Institute, Nanjing Medical University, Nanjing, Jiangsu, China. gao11@hotmail.com.
Abstract
BACKGROUND: The purpose of this study was to identify ferroptosis-related genes (FRGs) associated with the prognosis of pancreatic cancer and to construct a prognostic model based on FRGs. METHODS: Based on pancreatic cancer data obtained from The Cancer Genome Atlas database, we established a prognostic model from 232 FRGs. A nomogram was constructed by combining the prognostic model and clinicopathological features. Gene Expression Omnibus datasets and tissue samples obtained from our center were utilized to validate the model. The relationship between risk score and immune cell infiltration was explored by CIBERSORT and TIMER. RESULTS: The prognostic model was established based on four FRGs (ENPP2, ATG4D, SLC2A1 and MAP3K5), and the risk score was demonstrated to be an independent risk factor in pancreatic cancer (HR 1.648, 95% CI 1.335-2.035, p < 0.001). Based on the median risk score, patients were divided into a high-risk group and a low-risk group. The low-risk group had a better prognosis than the high-risk group. In the high-risk group, patients treated with chemotherapy had a better prognosis. The nomogram showed that the model was the most important element. Gene set enrichment analysis identified three key pathways, namely, TGFβ signaling, HIF signaling pathway and the adherens junction. The prognostic model may be associated with infiltration of immune cells such as M0 macrophages, M1 macrophages, CD4 + T cells and CD8 + T cells. CONCLUSION: The ferroptosis-related prognostic model can be employed to predict the prognosis of pancreatic cancer. Ferroptosis is an important marker, and immunotherapy may be a potential therapeutic target for pancreatic cancer.
BACKGROUND: The purpose of this study was to identify ferroptosis-related genes (FRGs) associated with the prognosis of pancreatic cancer and to construct a prognostic model based on FRGs. METHODS: Based on pancreatic cancer data obtained from The Cancer Genome Atlas database, we established a prognostic model from 232 FRGs. A nomogram was constructed by combining the prognostic model and clinicopathological features. Gene Expression Omnibus datasets and tissue samples obtained from our center were utilized to validate the model. The relationship between risk score and immune cell infiltration was explored by CIBERSORT and TIMER. RESULTS: The prognostic model was established based on four FRGs (ENPP2, ATG4D, SLC2A1 and MAP3K5), and the risk score was demonstrated to be an independent risk factor in pancreatic cancer (HR 1.648, 95% CI 1.335-2.035, p < 0.001). Based on the median risk score, patients were divided into a high-risk group and a low-risk group. The low-risk group had a better prognosis than the high-risk group. In the high-risk group, patients treated with chemotherapy had a better prognosis. The nomogram showed that the model was the most important element. Gene set enrichment analysis identified three key pathways, namely, TGFβ signaling, HIF signaling pathway and the adherens junction. The prognostic model may be associated with infiltration of immune cells such as M0 macrophages, M1 macrophages, CD4 + T cells and CD8 + T cells. CONCLUSION: The ferroptosis-related prognostic model can be employed to predict the prognosis of pancreatic cancer. Ferroptosis is an important marker, and immunotherapy may be a potential therapeutic target for pancreatic cancer.
Authors: Emma Lachaier; Christophe Louandre; Corinne Godin; Zuzana Saidak; Maxime Baert; Momar Diouf; Bruno Chauffert; Antoine Galmiche Journal: Anticancer Res Date: 2014-11 Impact factor: 2.480
Authors: Lola Rahib; Benjamin D Smith; Rhonda Aizenberg; Allison B Rosenzweig; Julie M Fleshman; Lynn M Matrisian Journal: Cancer Res Date: 2014-06-01 Impact factor: 12.701
Authors: Scott J Dixon; Kathryn M Lemberg; Michael R Lamprecht; Rachid Skouta; Eleina M Zaitsev; Caroline E Gleason; Darpan N Patel; Andras J Bauer; Alexandra M Cantley; Wan Seok Yang; Barclay Morrison; Brent R Stockwell Journal: Cell Date: 2012-05-25 Impact factor: 41.582
Authors: Chao Mao; Xiang Wang; Yating Liu; Min Wang; Bin Yan; Yiqun Jiang; Ying Shi; Yi Shen; Xiaoli Liu; Weiwei Lai; Rui Yang; Desheng Xiao; Yan Cheng; Shuang Liu; Hu Zhou; Ya Cao; Weishi Yu; Kathrin Muegge; Herbert Yu; Yongguang Tao Journal: Cancer Res Date: 2018-03-27 Impact factor: 12.701
Authors: John P Neoptolemos; Jörg Kleeff; Patrick Michl; Eithne Costello; William Greenhalf; Daniel H Palmer Journal: Nat Rev Gastroenterol Hepatol Date: 2018-06 Impact factor: 46.802
Authors: Scott J Dixon; Darpan N Patel; Matthew Welsch; Rachid Skouta; Eric D Lee; Miki Hayano; Ajit G Thomas; Caroline E Gleason; Nicholas P Tatonetti; Barbara S Slusher; Brent R Stockwell Journal: Elife Date: 2014-05-20 Impact factor: 8.140